Midkine Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK Pipeline Review, H1 2018
Summary
According to the recently published report 'Midkine Pipeline Review, H1 2018'; Midkine Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
Midkine Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK Midkine MDK or neurite growthpromoting factor 2 is a protein encoded by the MDK gene. It binds to anaplastic lymphoma kinase which induces ALK activation and subsequent phosphorylation of the insulin receptor substrate, activation of mitogenactivated protein kinase and PI3kinase and the induction of cell proliferation. It is involved in neointima formation after arterial injury and early fetal adrenal gland development.
The report 'Midkine Pipeline Review, H1 2018' outlays comprehensive information on the Midkine Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Midkine Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Gastrointestinal, Musculoskeletal Disorders, Cardiovascular and Respiratory which include indications Inflammation, Diabetic Nephropathy, Kidney Fibrosis, Liver Fibrosis, NonSmall Cell Lung Cancer, Acute Renal Failure ARF Acute Kidney Injury, Autoimmune Disorders, Bone Disorders, Bone Fracture, Chronic Kidney Disease Chronic Renal Failure, Fibrosis, Focal Segmental Glomerulosclerosis FSGS, Glioblastoma Multiforme GBM, Glomerulonephritis, Ischemia Reperfusion Injury, Kidney Disease, Lung Disease, Neuroblastoma, Osteoporosis, Osteosarcoma, Prostate Cancer, Solid Tumor and Squamous NonSmall Cell Lung Cancer.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Midkine Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK
The report reviews Midkine Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Midkine Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK targeted therapeutics and enlists all their major and minor projects
The report assesses Midkine Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Midkine Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Midkine Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Midkine Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope